Clinical trials
Psilocybin clinical trials
Below are recruiting psilocybin clinical trials, each written for real people, not researchers. We’re tracking 100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06464367RecruitingEarly Phase 1
Psilocybin study for migraine and healthy volunteers
This study looks at how psilocybin affects the brain in people with migraines and in healthy volunteers. The goal is to understand why it may help with headache disorders.
West Haven, ConnecticutAges 21–70 - NCT05068791RecruitingEarly Phase 1
Psilocybin-assisted treatment for long-term body pain
This early trial studies whether psilocybin, given in a supported setting, can reduce long-term widespread musculoskeletal pain (including fibromyalgia-like symptoms). You would be monitored closely and need someone to take you home after the medicine session.
Birmingham, AlabamaAges 25–65 - NCT05452772RecruitingPhase 2
Psilocybin plus niacin to help quit smoking
This Phase 2 study tests whether a psilocybin “session” with niacin can help people quit smoking. It’s for adults who smoke daily and want to quit but have tried and struggled before.
Birmingham, AlabamaAges 21 years+ - NCT05585229RecruitingPhase 2
Psilocybin therapy to help you taper opioid pain medicine
This Phase 2 study tests a structured, therapist-led treatment using standardized natural psilocybin to help people reduce or stop long-term opioid use for chronic (non-cancer) pain. It’s mainly for those who have tried tapering before but couldn’t, and who are motivated to try again.
Kelowna, British ColumbiaAges 19–75 - NCT05866471RecruitingPhase 1
Testing nerve stimulation plus psilocybin for emotional well-being
This early safety study tests whether stimulating a nerve (taVNS) combined with psilocybin can change emotional well-being. It also checks safety issues like heart rhythms, lab results, and whether fMRI brain scans are possible.
Madison, WisconsinAges 18–70 - NCT05995769RecruitingPhase 2
Psilocybin therapy with talk therapy for alcohol problems
This trial tests whether psilocybin (the active ingredient in magic mushrooms), given with talk therapy, can help people who want to reduce their heavy drinking. It is for people with at least moderate alcohol use disorder who are motivated to change.
Calgary, AlbertaAges 22–65 - NCT06072898RecruitingPhase 2
Psilocybin brain imaging trial for depression
This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.
Toronto, OntarioAges 18–64 - NCT06225232RecruitingPhase 2
Psilocybin for cannabis use disorder
This trial tests whether a single dose of psilocybin (a psychedelic compound) can help people with moderate to severe cannabis use disorder reduce or stop their cannabis use. You will receive the drug in a supervised setting and have follow-up check-ins.
Hamilton, OntarioAges 18–65 - NCT06367738RecruitingPhase 1
Psilocybin and brain changes in healthy older adults
This study looks at how a single dose of psilocybin (the active ingredient in magic mushrooms) affects brain structure in healthy older adults. You'll receive the drug in a safe setting and have brain scans before and after to see if it promotes positive changes.
Berkeley, CaliforniaAges 60–85 - NCT06368492Recruiting
Psilocybin for fibromyalgia pain
This trial tests whether psilocybin, a substance found in certain mushrooms, can help reduce pain in people with fibromyalgia. You would receive the drug and be monitored closely to see if it improves your pain levels.
Maastricht, LimburgAges 18–65 - NCT06378229RecruitingPhase 2
Psilocybin for hospitalized treatment-resistant depression
This trial tests whether a single dose of psilocybin can help hospitalized patients with tough-to-treat depression. It focuses on people who haven't improved with standard antidepressants and need a new option.
Ghent, Oost-VlaanderenAges 18 years+ - NCT06386003RecruitingPhase 2
Psilocybin and talk therapy for chronic PTSD
This trial tests whether a medication called psilocybin (the active ingredient in magic mushrooms) can help people with long-term PTSD when combined with a specific type of talk therapy. The goal is to see if this approach reduces PTSD symptoms more than therapy alone.
Toronto, OntarioAges 18–65 - NCT06399263RecruitingPhase 2
Psilocybin for anorexia in young adults
This trial tests whether a single dose of psilocybin (a psychedelic substance) can help treat anorexia nervosa in young adults. It involves taking the medication in a safe, supervised setting and participating in therapy sessions with a support person.
San Francisco, CaliforniaAges 18–25 - NCT06405607RecruitingPhase 2
Psilocybin vs Ketamine for Alcohol Use Disorder Trial
This trial tests two psychedelic-assisted therapies, psilocybin and ketamine, to see which works better for reducing heavy drinking in people with alcohol use disorder (AUD). You'll receive either drug along with counseling, and the study monitors safety closely.
Iowa City, IowaAges 21–65 - NCT06430541RecruitingPhase 1
Psilocybin therapy for fear of cancer recurrence
This trial tests if psilocybin-assisted therapy can help reduce the intense worry that cancer might come back. It is for people who have finished their main treatments for early-stage breast cancer or advanced ovarian cancer.
Aurora, ColoradoAges 21 years+ - NCT06442423RecruitingPhase 1
Psilocybin study for people with psychiatric symptoms
This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.
New Haven, ConnecticutAges 18 years+ - NCT06455293RecruitingPhase 2
Psilocybin therapy for depression in Parkinson's disease
This study tests whether psilocybin, a substance found in certain mushrooms, can help improve depression in people with Parkinson's disease. If you have Parkinson's and are feeling depressed, this treatment may offer a new option.
San Francisco, CaliforniaAges 40–80 - NCT06615908RecruitingPhase 1
Psilocybin therapy for lingering concussion symptoms
This study tests whether a single dose of psilocybin, given with therapist support, can reduce long-lasting symptoms after a concussion. If your symptoms have continued for months, you may be eligible.
Calgary, AlbertaAges 18–65 - NCT06660381RecruitingPhase 1
Psilocybin therapy for cannabis use disorder
This study tests if psilocybin (a substance that can change how you think and feel) can help people reduce or stop using cannabis. You will receive support and be monitored closely throughout the trial.
Baltimore, MarylandAges 18 years+ - NCT04161066RecruitingPhase 1
Psilocybin plus buprenorphine to help opioid use disorder symptoms
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
Madison, WisconsinAges 21–65 - NCT06160284RecruitingPhase 1
Psilocybin for brain healing in opioid recovery
This study tests whether psilocybin, a psychedelic substance, can help change brain connections in people recovering from opioid use disorder. It involves brain scans and careful medical monitoring to explore new treatment options.
New Haven, ConnecticutAges 25–55 - NCT06724289RecruitingEarly Phase 1
Psilocybin for prolonged grief
This trial tests if a single dose of psilocybin (a psychedelic drug) can help people with prolonged grief disorder. You'll receive counseling and be observed in a safe setting.
Charlottesville, VirginiaAges 18–65 - NCT06731335RecruitingPhase 2
Psilocybin for chronic nerve pain that hasn't improved with other treatments
This study tests whether psilocybin (a compound found in certain mushrooms) can help reduce chronic nerve pain that has not responded well to standard medications. You will receive study treatment plus psychotherapy to see if it improves your pain.
Toronto, OntarioAges 18–65 - NCT06782724RecruitingPhase 2
Psilocybin therapy for distress in advanced illness
This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.
PragueAges 18 years+
Hear when a new Psilocybin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psilocybin?
- Yes. Clin2 currently lists 100 recruiting psilocybin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psilocybin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psilocybin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.